Entasis Therapeutics
Biotechnology company focused on development, regulatory approval, and commercial delivery of therapies for critical care and infectious diseases. Activities include clinical development (Phase 1–3), antimicrobial R&D, pharmacokinetic/pharmacodynamic and microbiology research, medical affairs (medical information, safety reporting, educational grants), and commercial partnerships.
Industries
Nr. of Employees
medium (51-250)
Entasis Therapeutics
Patents
Products
GIAPREZA (angiotensin II)
Intravenous angiotensin II product indicated as a vasopressor for certain patients with vasodilatory shock; supported by clinical studies and postmarketing research.
NUZOLVENCE (zoliflodacin)
Oral single‑dose antibiotic for treatment of uncomplicated urogenital gonorrhea; developed through clinical trials and public‑private collaboration.
XACDURO (sulbactam; durlobactam)
Intravenous beta‑lactam/beta‑lactamase inhibitor combination developed to treat multidrug‑resistant Acinetobacter infections; supported by Phase 3 clinical data and microbiology studies.
XERAVA (eravacycline)
Intravenous tetracycline‑class antibiotic indicated for complicated intra‑abdominal infections; supported by clinical trials and PK/PD studies.
ZEVTERA (ceftobiprole medocaril sodium)
Advanced‑generation cephalosporin antibiotic for treatment of various bacterial infections, including certain MRSA indications and pediatric evaluations.
GIAPREZA
Angiotensin II therapy indicated for patients in critical care.
GIAPREZA (angiotensin II)
Intravenous angiotensin II product indicated as a vasopressor for certain patients with vasodilatory shock; supported by clinical studies and postmarketing research.
NUZOLVENCE (zoliflodacin)
Oral single‑dose antibiotic for treatment of uncomplicated urogenital gonorrhea; developed through clinical trials and public‑private collaboration.
XACDURO (sulbactam; durlobactam)
Intravenous beta‑lactam/beta‑lactamase inhibitor combination developed to treat multidrug‑resistant Acinetobacter infections; supported by Phase 3 clinical data and microbiology studies.
XERAVA (eravacycline)
Intravenous tetracycline‑class antibiotic indicated for complicated intra‑abdominal infections; supported by clinical trials and PK/PD studies.
ZEVTERA (ceftobiprole medocaril sodium)
Advanced‑generation cephalosporin antibiotic for treatment of various bacterial infections, including certain MRSA indications and pediatric evaluations.
GIAPREZA
Angiotensin II therapy indicated for patients in critical care.
Services
Telephone and email-based medical information services for healthcare professionals in the U.S.; adverse event and product complaint intake and triage.
Funding and support for investigator-led clinical and preclinical research and independent medical education activities.
Telephone and email-based medical information services for healthcare professionals in the U.S.; adverse event and product complaint intake and triage.
Funding and support for investigator-led clinical and preclinical research and independent medical education activities.
Expertise Areas
- Infectious disease therapeutics development
- Critical care therapeutics
- Clinical trial management (including multinational Phase 3 studies)
- Pharmacokinetics, PK/PD and pharmacometrics
Key Technologies
- Phase 1–3 clinical trials
- Multinational pivotal Phase 3 trial execution
- Population pharmacokinetic (PPK) modeling
- Pharmacokinetic/pharmacodynamic (PK/PD) analysis
News & Updates
FDA approved a first-in-class single‑dose oral antibiotic for treatment of uncomplicated urogenital gonorrhea in adults and adolescents.
Positive Phase 3 trial results demonstrating non-inferiority of a single-dose oral regimen vs standard injectable therapy were published in a peer‑reviewed high‑impact journal.
FDA accepted a New Drug Application for a first‑in‑class oral antibiotic for uncomplicated gonorrhea.
Presented subgroup analyses and in vitro susceptibility findings from the pivotal Phase 3 trial at a major infectious disease meeting.
Executed an exclusive distribution and licensing agreement with an international partner to develop and commercialize an anti‑infective product in specified territories.
Earned a strong performance rating in the Access to Medicine Foundation’s 2026 AMR Benchmark for R&D alignment with WHO priorities and integration of access/stewardship planning.
FDA approved a first-in-class single‑dose oral antibiotic for treatment of uncomplicated urogenital gonorrhea in adults and adolescents.
Positive Phase 3 trial results demonstrating non-inferiority of a single-dose oral regimen vs standard injectable therapy were published in a peer‑reviewed high‑impact journal.
FDA accepted a New Drug Application for a first‑in‑class oral antibiotic for uncomplicated gonorrhea.
Presented subgroup analyses and in vitro susceptibility findings from the pivotal Phase 3 trial at a major infectious disease meeting.
Executed an exclusive distribution and licensing agreement with an international partner to develop and commercialize an anti‑infective product in specified territories.
Earned a strong performance rating in the Access to Medicine Foundation’s 2026 AMR Benchmark for R&D alignment with WHO priorities and integration of access/stewardship planning.